{"id":"doxorubicin-eluting-beads","safety":{"commonSideEffects":[{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Post-embolization syndrome"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These beads are loaded with doxorubicin and injected into the arterial blood supply feeding a tumor, where they lodge in tumor vasculature. This approach delivers high local concentrations of doxorubicin while simultaneously occluding blood flow to starve the tumor of oxygen and nutrients. The dual mechanism of chemotherapy and embolization maximizes tumor kill while minimizing systemic exposure.","oneSentence":"Doxorubicin-eluting beads deliver the chemotherapy drug doxorubicin directly to tumors via transcatheter arterial chemoembolization, combining local drug delivery with ischemic tumor necrosis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:10:02.638Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatocellular carcinoma"},{"name":"Liver metastases"}]},"trialDetails":[{"nctId":"NCT03937830","phase":"PHASE2","title":"Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-03-10","conditions":"Hepatocellular Cancer, Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma","enrollment":27},{"nctId":"NCT07449065","phase":"","title":"CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC","status":"COMPLETED","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2018-06-01","conditions":"Hepatocellular Carcinoma (HCC), Transarterial Chemoembolization, Microvascular Invasion (MVI)","enrollment":324},{"nctId":"NCT07302919","phase":"PHASE2, PHASE3","title":"Transarterial Chemoembolization (TACE) Plus ABCB1 Inhibition Versus TACE Alone in Patients With Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2026-02-16","conditions":"Hepato Cellular Carcinoma (HCC)","enrollment":152},{"nctId":"NCT07322848","phase":"PHASE3","title":"DEB-TACE vs cTACE in HCC After TIPS","status":"RECRUITING","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2025-12-01","conditions":"Hepatocellular Carcinoma (HCC), TACE, TIPS","enrollment":206},{"nctId":"NCT07168668","phase":"PHASE2","title":"Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment","status":"NOT_YET_RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2025-09-15","conditions":"HCC, Tace, Immunotherapy","enrollment":90},{"nctId":"NCT02724540","phase":"PHASE2","title":"Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2016-03","conditions":"Neuroendocrine Tumor, Malignant, Liver Metastases","enrollment":162},{"nctId":"NCT03960008","phase":"PHASE3","title":"Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant","status":"TERMINATED","sponsor":"Lahey Clinic","startDate":"2020-03-01","conditions":"Hepatocellular Carcinoma, HCC","enrollment":9},{"nctId":"NCT02182687","phase":"PHASE2","title":"Stereotactic Body Radiation Therapy (SBRT) Versus Trans-Arterial Chemoembolization (TACE) as Bridge to Liver Transplant","status":"COMPLETED","sponsor":"Lahey Clinic","startDate":"2014-06","conditions":"Hepatocellular Carcinoma, HCC","enrollment":60},{"nctId":"NCT04103398","phase":"PHASE3","title":"TACE Plus Sorafenib Versus TACE Alone for Recurrent Intermediate Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2019-10-02","conditions":"Hepatocellular Carcinoma, Sorafenib, Transarterial Chemoembolization","enrollment":162},{"nctId":"NCT06261138","phase":"","title":"Survival Analysis: TACE vs. Combination Therapy in HCC","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2019-02-01","conditions":"Hepatocellular Carcinoma","enrollment":279},{"nctId":"NCT06194695","phase":"","title":"DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma","status":"UNKNOWN","sponsor":"Ze-yang Ding, MD","startDate":"2022-02-01","conditions":"Cholangiocarcinoma Non-resectable","enrollment":100},{"nctId":"NCT06192784","phase":"PHASE2","title":"Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma","status":"UNKNOWN","sponsor":"Tongji Hospital","startDate":"2023-12-09","conditions":"Cholangiocarcinoma Non-resectable","enrollment":36},{"nctId":"NCT01004978","phase":"PHASE3","title":"Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-10-28","conditions":"Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma","enrollment":235},{"nctId":"NCT00539643","phase":"PHASE2","title":"Trial of Beads Versus Doxorubicin Eluting Beads for Arterial Embolization of Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2007-11","conditions":"Hepatocellular Carcinoma, Liver Cancer, Hepatoma","enrollment":101},{"nctId":"NCT05093920","phase":"EARLY_PHASE1","title":"Role of DEB-TACE Versus c-TACE in Treatment of HCC","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2022-01-01","conditions":"Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT01381211","phase":"PHASE2","title":"Transarterial RAdioembolization Versus ChemoEmbolization for the Treatment of Hepatocellular Carcinoma (HCC)","status":"TERMINATED","sponsor":"University Hospital, Ghent","startDate":"2011-09","conditions":"Hepatocellular Carcinoma","enrollment":72},{"nctId":"NCT02794337","phase":"PHASE2, PHASE3","title":"TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer","status":"UNKNOWN","sponsor":"Tata Memorial Hospital","startDate":"2014-12","conditions":"Carcinoma, Hepatocellular","enrollment":67},{"nctId":"NCT03966742","phase":"PHASE2","title":"Doxorubicin Eluting Intra-arterial Embolization for Aggressive Desmoid Fibromatosis","status":"COMPLETED","sponsor":"Rabin Medical Center","startDate":"2018-10-11","conditions":"Desmoid, Desmoid Fibromatosis of Skin, Desmoid Neoplasm of Chest Wall","enrollment":8},{"nctId":"NCT03474354","phase":"","title":"DC Bead LUMI (TM) Loaded With Doxorubicin for Intermediate Hepatocellular Carcinoma (HCC)","status":"COMPLETED","sponsor":"Malagari Katerina","startDate":"2018-05-02","conditions":"Hepatocellular Cancer, Chemoembolization","enrollment":50},{"nctId":"NCT00844883","phase":"PHASE2","title":"Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Yale University","startDate":"2009-02","conditions":"Hepatocellular Carcinoma, Hepatoma","enrollment":50},{"nctId":"NCT00261378","phase":"PHASE2","title":"Prospective Randomised Study of Doxorubicin in the Treatment of Hepatocellular Carcinoma by Drug-Eluting Bead Embolisation","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2005-11","conditions":"Primary Liver Cancer","enrollment":212},{"nctId":"NCT03452553","phase":"NA","title":"Study in the Treatment of HCC With a Radiopaque (RO) Bead (LC Bead LUMI™) Loaded With Doxorubicin","status":"WITHDRAWN","sponsor":"Boston Scientific Corporation","startDate":"2018-07-01","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":""},{"nctId":"NCT02670122","phase":"","title":"Prospective Study to Evaluate Safety of Deb-TACE With 100µ Beads in Patients With Non Resectable HCC","status":"COMPLETED","sponsor":"Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz","startDate":"2015-03","conditions":"Hepatocellular Carcinoma","enrollment":131},{"nctId":"NCT04803019","phase":"PHASE3","title":"Transarterial Embolization Alone Versus Drug-Eluting Beads Chemoembolization for Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2019-12-04","conditions":"Carcinoma, Hepatocellular","enrollment":154},{"nctId":"NCT02460991","phase":"PHASE3","title":"A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma","status":"TERMINATED","sponsor":"Boston Scientific Corporation","startDate":"2015-11","conditions":"Hepatocellular Carcinoma, Hepatoma, Liver Cell Carcinoma","enrollment":2},{"nctId":"NCT04738188","phase":"NA","title":"Efficacy and Safety of TACE on Downstaging Hepatocellular Carcinoma Beyond UCSF Criteria;","status":"UNKNOWN","sponsor":"Beijing Tsinghua Chang Gung Hospital","startDate":"2020-03-18","conditions":"Hepatocellular Carcinoma","enrollment":226},{"nctId":"NCT02470533","phase":"PHASE2","title":"Transarterial Chemoembolization Versus Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma","status":"TERMINATED","sponsor":"Erasmus Medical Center","startDate":"2015-04-30","conditions":"Liver Neoplasms","enrollment":100},{"nctId":"NCT03007225","phase":"PHASE4","title":"Efficacy and Safety of Drug Eluting Beads TACE in Treatment of HCC in Egyptian Patients","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2015-07","conditions":"HepatoCellular Carcinoma","enrollment":50},{"nctId":"NCT03969576","phase":"NA","title":"Drug-eluting Bead Transarterial Chemoembolisation (DEB-TACE) Versus (VS) Conventional Transarterial Chemoembolisation (cTACE) for Unresectable Hepatocellualr Carcinoma (HCC)","status":"UNKNOWN","sponsor":"Air Force Military Medical University, China","startDate":"2020-09-15","conditions":"Hepatocellular Carcinoma","enrollment":344},{"nctId":"NCT02147301","phase":"NA","title":"TACE Using Doxorubicin-eluting Beads for Patients With HCC and Marginal Hepatic Reserve","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2014-12-17","conditions":"Hepatocellular Carcinoma, Chemoembolization","enrollment":17},{"nctId":"NCT04048317","phase":"EARLY_PHASE1","title":"Effectiveness of Drug Eluting TACE in Primary HCC","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-09-01","conditions":"Hepatic Cell Carcinoma","enrollment":75},{"nctId":"NCT01891539","phase":"","title":"Observational Prospective Study on Chemoembolization With Doxorubicin for Unresectable Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"International Group of Endovascular Oncology","startDate":"2013-05","conditions":"Liver Cell Carcinoma Non-resectable","enrollment":100},{"nctId":"NCT03299036","phase":"NA","title":"Drug-loadable（T-ACE Beads）for Hepatoma Embolization Therapy","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2017-06-01","conditions":"Cancer of Liver","enrollment":12},{"nctId":"NCT00293397","phase":"NA","title":"Chemoembolization Using Doxorubicin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery","status":"COMPLETED","sponsor":"Yale University","startDate":"2005-11","conditions":"Liver Cancer","enrollment":20},{"nctId":"NCT02748161","phase":"NA","title":"DEB-TACE for Hepatocellular Carcinoma","status":"TERMINATED","sponsor":"Surefire Medical, Inc.","startDate":"2015-08","conditions":"Hepatocellular Carcinoma","enrollment":170},{"nctId":"NCT01259024","phase":"NA","title":"The LC Bead Trial; Transarterial Chemoembolization of Hepatocellular Carcinoma (HCC)With a Drug-eluting Bead","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2011-12","conditions":"Hepatocellular Carcinoma","enrollment":1},{"nctId":"NCT02525380","phase":"PHASE4","title":"Safety and Efficacy of Doxorubicin-eluting-bead Embolization in Patients With Advanced Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2015-09","conditions":"Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT02958163","phase":"PHASE2","title":"Clinical Trial Comparing TACE With TACE + SABR in Stage BCLC B HCC (HepSTAR)","status":"TERMINATED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2017-02-20","conditions":"Liver Neoplasms, Hepatocellular Cancer","enrollment":3},{"nctId":"NCT01489410","phase":"NA","title":"Comparing Lipiodol/Ethanol With Drug-eluting Beads (DEB) for Hepatocellular Carcinoma","status":"WITHDRAWN","sponsor":"University of Minnesota","startDate":"2012-10","conditions":"Hepatocellular Carcinoma","enrollment":""},{"nctId":"NCT00730483","phase":"NA","title":"Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors","status":"TERMINATED","sponsor":"Yale University","startDate":"2009-02","conditions":"Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Metastatic Cancer","enrollment":13},{"nctId":"NCT02007954","phase":"PHASE2","title":"Doxorubicin-eluting LC Bead M1 for Patients With Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Yale University","startDate":"2014-02","conditions":"Hepatocellular Carcinoma","enrollment":24},{"nctId":"NCT01798147","phase":"PHASE2","title":"Selective Internal Radiotherapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Cholangiocellular Carcinoma (CCC).","status":"UNKNOWN","sponsor":"Johannes Gutenberg University Mainz","startDate":"2011-02","conditions":"Intrahepatic Cholangiocellular Carcinoma","enrollment":24},{"nctId":"NCT00877071","phase":"PHASE2","title":"LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2008-11","conditions":"Hepatocellular Carcinoma","enrollment":2},{"nctId":"NCT01798160","phase":"PHASE4","title":"Selective Internal Radiation Therapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Hepatocellular Carcinoma (HCC).","status":"COMPLETED","sponsor":"Johannes Gutenberg University Mainz","startDate":"2010-02","conditions":"Hepatocellular Carcinoma","enrollment":24},{"nctId":"NCT01009801","phase":"PHASE1, PHASE2","title":"Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer","status":"TERMINATED","sponsor":"Swiss Cancer Institute","startDate":"2010-02","conditions":"Liver Cancer","enrollment":27},{"nctId":"NCT01332669","phase":"PHASE4","title":"Drug-eluting Bead in Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2011-04","conditions":"Hepatocellular Carcinoma","enrollment":200},{"nctId":"NCT02070419","phase":"PHASE2","title":"TACE With or Without Radiation Therapy in Treating Patients With Stage A-C Liver Cancer","status":"WITHDRAWN","sponsor":"Case Comprehensive Cancer Center","startDate":"2014-04","conditions":"Adult Primary Hepatocellular Carcinoma, Recurrent Adult Primary Liver Cancer, Stage I Adult Primary Liver Cancer","enrollment":""},{"nctId":"NCT01116635","phase":"PHASE1, PHASE2","title":"Clinical Study Examining the Safety and Efficacy of Doxorubicin Drug Eluting Microspheres Transarterial Embolization in the Setting of Hepatocellular Carcinoma (HCC)","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2010-01","conditions":"Hepatocellular Carcinoma","enrollment":24},{"nctId":"NCT01409733","phase":"PHASE1, PHASE2","title":"TACE With Drug Eluting Beads Loaded With Doxorubicin in Liver Metastases From Melanoma Patients","status":"UNKNOWN","sponsor":"Heidelberg University","startDate":"2010-06","conditions":"Stage IV Melanoma Patients With Unresectable Liver Metastases","enrollment":20},{"nctId":"NCT01324076","phase":"PHASE3","title":"Transarterial Chemoembolization Using Doxorubicin Beads With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery","status":"UNKNOWN","sponsor":"University College, London","startDate":"2010-11","conditions":"Liver Cancer","enrollment":412}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":56,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Adriamycin","Lipidol-Doxorubicin emulsion"],"phase":"phase_3","status":"active","brandName":"doxorubicin-eluting beads","genericName":"doxorubicin-eluting beads","companyName":"Swiss Cancer Institute","companyId":"swiss-cancer-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Doxorubicin-eluting beads deliver the chemotherapy drug doxorubicin directly to tumors via transcatheter arterial chemoembolization, combining local drug delivery with ischemic tumor necrosis. Used for Hepatocellular carcinoma, Liver metastases.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}